Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Condition(s):SCLC, Extensive StageLast Updated:April 12, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):SCLC, Extensive StageLast Updated:April 12, 2022Recruiting
Condition(s):Small-cell Lung Cancer; Extensive-stage Small-cell Lung CancerLast Updated:March 9, 2023Recruiting
Condition(s):Small-cell Lung Cancer; Extensive-stage Small-cell Lung Cancer; Lung CancerLast Updated:February 16, 2023Recruiting
Condition(s):Small Cell Lung CancerLast Updated:April 3, 2023Not yet recruiting
Condition(s):Small-cell Lung CancerLast Updated:March 25, 2024Recruiting
Condition(s):Small Cell Lung CancerLast Updated:February 1, 2018Completed
Condition(s):Limited Stage Small Cell Lung Cancer; Extensive-stage Small-cell Lung CancerLast Updated:November 3, 2023Recruiting
Condition(s):Limited Stage Small Cell Lung CancerLast Updated:September 5, 2021Recruiting
Condition(s):Small-cell Lung Cancer; Small Cell Lung CarcinomaLast Updated:June 14, 2022Terminated
Condition(s):Small Cell Lung CancerLast Updated:June 18, 2013Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.